Dyslipidemia is associated with tunneled-cuffed catheter-related central venous thrombosis in hemodialysis patients: A retrospective, multicenter study

Artificial Organs

Volumn 37, Issue 8, 2013, Pages

  Cheng, Yuan ^a   Cui, Tianlei ^a   Fu, Ping ^a   Liu, Fang ^a   Zhou, Li ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Central venous thrombosis; Dyslipidemia; Hemodialysis; Low serum albumin; Tunneled cuffed catheters

Indexed keywords

BLOOD VESSELS; BODY FLUIDS; CATHETERS; CHOLESTEROL; DIAGNOSIS; DISEASES; HEMODIALYZERS; LIPOPROTEINS;

CENTRAL VENOI THROMBOSE; CONTROL GROUPS; DYSLIPIDEMIAS; HAEMODIALYSIS; HDL CHOLESTEROLS; HEMODIALYSIS PATIENT; LOW SERUM ALBUMIN; SERUM ALBUMIN; TUNNELED CUFFED CATHETERS; VENOUS THROMBOSIS;

DIALYSIS;

ALBUMIN; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ALBUMIN BLOOD LEVEL; ANTICOAGULATION; ARTICLE; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ACCESS; VEIN THROMBOSIS;

CENTRAL VENOUS THROMBOSIS; DYSLIPIDEMIA; HEMODIALYSIS; LOW SERUM ALBUMIN; TUNNELED-CUFFED CATHETERS;

AGED; CASE-CONTROL STUDIES; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; SERUM ALBUMIN; VENOUS THROMBOSIS;

EID: 84881616341     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12086     Document Type: Article

References (29)

1. Rehman R, Schmidt RJ, Moss AH. Ethical and legal obligation to avoid long-term tunneled catheter access. Clin J Am Soc Nephrol: CJASN 2009;4:456-460.
2. Wilkin TD, Kraus MA, Lane KA, Trerotola SO. Internal jugular vein thrombosis associated with hemodialysis catheters. Radiology 2003;228:697-700.
3. Agarwal AK. Central vein stenosis: current concepts. Adv Chronic Kidney Dis 2009;16:360-370.
4. Cui T, Li Z, Yang Y, et al. Multi-detector computed tomography venography in the assessment of dysfunction of tunneled hemodialysis central vein catheters. J Vasc Access 2012;13:388-392.
5. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006;98:1352-1364.
6. Frederiksen J, Juul K, Grande P, et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood 2004;104:3046-3051.
7. Jang MJ, Choi WI, Bang SM, et al. Metabolic syndrome is associated with venous thromboembolism in the Korean population. Arterioscler Thromb Vasc Biol 2009;29:311-315.
8. Ay C, Tengler T, Vormittag R, et al. Venous thromboembolism-a manifestation of the metabolic syndrome. Haematologica 2007;92:374-380.
9. Kirkpantur A, Arici M, Altun B, et al. Association of serum lipid profile and arteriovenous fistula thrombosis in maintenance hemodialysis patients. Blood Purif 2008;26:322-332.
10. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008;117:93-102.
11. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;41:S1-91.
12. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
13. Enomoto M, Adachi H, Hirai Y, et al. LDL-C/HDL-C ratio predicts carotid intima-media thickness progression better than HDL-C or LDL-C alone. J Lipid 2011;2011:549137.
14. Bray PF, Larson JC, Lacroix AZ, et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 2008;101:1599-1605.
15. Gonzalez-Ordonez AJ, Fernandez-Carreira JM, Fernandez-Alvarez CR, et al. The concentrations of soluble vascular cell adhesion molecule-1 and lipids are independently associated with venous thromboembolism. Haematologica 2003;88:1035-1043.
16. Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006;26:523-539.
17. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-1407.
18. Fellstrom BC. Cardioprotective role of statins in chronic kidney disease: do we have the answer? Kidney Int 2011;79:931-932.
19. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-2192.
20. Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009;7:514-520.
21. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851-1861.
22. Bellomo R, Wood C, Wagner I, et al. Idiopathic membranous nephropathy in an Australian population: the incidence of thromboembolism and its impact on the natural history. Nephron 1993;63:240-241.
23. Gigante A, Barbano B, Sardo L, et al. Hypercoagulability and nephrotic syndrome. Curr Vasc Pharmacol 2012; Jun 22. [Epub ahead of print].
24. Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin and risk of venous thromboembolism. Thromb Haemost 2010;104:100-104.
25. Shapiro R, Vogel JD, Kiran RP. Risk of postoperative venous thromboembolism after laparoscopic and open colorectal surgery: an additional benefit of the minimally invasive approach? Dis Colon Rectum 2011;54:1496-1502.
26. Montagnana M, Meschi T, Borghi L, Lippi G. Thrombosis and occlusion of vascular access in hemodialyzed patients. Semin Thromb Hemost 2011;37:946-954.
27. Ikizler TA, Pupim LB, Brouillette JR, et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab 2002;282:E107-116.
28. Tonbul HZ, Demir M, Altintepe L, et al. Malnutrition-inflammation-atherosclerosis (MIA) syndrome components in hemodialysis and peritoneal dialysis patients. Renal Fail 2006;28:287-294.
29. Quist-Paulsen P, Naess IA, Cannegieter SC, et al. Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica 2010;95:119-125.